Delayed
Australian S.E.
11:40:06 24/08/2023 am IST
|
5-day change
|
1st Jan Change
|
0.01
AUD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: June |
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
76.2
|
26.95
|
11.53
|
-
|
Enterprise Value (EV)
1 |
76.2
|
26.95
|
11.53
|
11.53
|
P/E ratio
|
-4.29
x
|
-140
x
|
-0.35
x
|
-0.31
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.9
x
|
44.9
x
|
5.52
x
|
5.27
x
|
EV / Revenue
|
13.9
x
|
44.9
x
|
5.52
x
|
5.27
x
|
EV / EBITDA
|
-3.66
x
|
-0.87
x
|
-0.33
x
|
-0.28
x
|
EV / FCF
|
-
|
-12,62,864
x
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,519
|
8,160
|
10,693
|
-
|
Reference price
2 |
10.13
|
3.303
|
1.079
|
1.079
|
Announcement Date
|
25/08/22
|
29/09/23
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
11.64
|
3.359
|
5.581
|
5.49
|
0.5996
|
2.09
|
2.19
|
EBITDA
1 |
-5.833
|
-1.737
|
-5.74
|
-20.8
|
-30.87
|
-34.6
|
-41.4
|
EBIT
1 |
-7.542
|
-4.18
|
-7.441
|
-21.91
|
-32.02
|
-36.52
|
-54.15
|
Operating Margin
|
-64.78%
|
-124.43%
|
-133.31%
|
-399.05%
|
-5,340.62%
|
-1,747.91%
|
-2,472.98%
|
Earnings before Tax (EBT)
1 |
-9.906
|
-6.027
|
-
|
-21.95
|
-32.05
|
-36.07
|
-53.65
|
Net income
1 |
-9.669
|
-7.118
|
-
|
-21.76
|
-31.85
|
-38.06
|
-55.64
|
Net margin
|
-83.05%
|
-211.89%
|
-
|
-396.36%
|
-5,311.01%
|
-1,821.66%
|
-2,541.08%
|
EPS
2 |
-
|
-
|
-
|
-2.360
|
-0.0236
|
-3.100
|
-3.520
|
Free Cash Flow
|
-15.68
|
-
|
-
|
-
|
-21.34
|
-
|
-
|
FCF margin
|
-134.69%
|
-
|
-
|
-
|
-3,559.36%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/08/19
|
28/08/20
|
25/08/21
|
25/08/22
|
29/09/23
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
|
4.608
|
1.528
|
6.148
|
-0.5663
|
0.08
|
0.08
|
-0.66
|
-
|
-
|
6.15
|
-
|
0.7395
|
-0.1399
|
-
|
2.7
|
EBITDA
|
-3.88
|
-
|
-3.41
|
-5.93
|
-
|
-
|
-11.11
|
-
|
-
|
-5.57
|
-
|
-
|
-
|
-
|
-17.3
|
EBIT
1 |
-5.698
|
1.291
|
-
|
-
|
-5.79
|
-5.79
|
-
|
-3.01
|
-3.01
|
-
|
-7.41
|
-16.3
|
-15.73
|
-
|
-
|
Operating Margin
|
-123.66%
|
84.47%
|
-
|
-
|
-7,237.5%
|
-7,237.5%
|
-
|
-
|
-
|
-
|
-
|
-2,203.75%
|
11,245.37%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.543
|
0.2891
|
-
|
-
|
-6.57
|
-6.57
|
-
|
-4.4
|
-4.4
|
-
|
-8.16
|
-16.31
|
-15.74
|
-
|
-16.8
|
Net income
1 |
-6.364
|
-0.7083
|
-
|
-
|
-6.53
|
-6.53
|
-
|
-4.35
|
-4.35
|
-
|
-8.1
|
-16.21
|
-15.64
|
-15.37
|
-16.7
|
Net margin
|
-138.1%
|
-46.34%
|
-
|
-
|
-8,162.5%
|
-8,162.5%
|
-
|
-
|
-
|
-
|
-
|
-2,191.75%
|
11,181.89%
|
-
|
-618.52%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.8260
|
-
|
-0.0142
|
-0.009400
|
-
|
-1.450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/20
|
28/08/20
|
26/02/21
|
25/08/21
|
23/02/23
|
23/02/22
|
23/02/22
|
25/08/22
|
25/08/22
|
25/08/22
|
23/02/23
|
23/02/23
|
29/09/23
|
15/03/24
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
3.11
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.5338
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-15.7
|
-
|
-
|
-
|
-21.3
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-56.3%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-16.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
58.17
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.1
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.85%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/08/19
|
28/08/20
|
25/08/21
|
25/08/22
|
29/09/23
|
-
|
-
|
Last Close Price
1.079
AUD Average target price
15.26
AUD Spread / Average Target +1,315.10% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|